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OBJECTIVES: To inform a multiple technology appraisal to be conducted by the 
National Institute for Health and Care Excellence on the use of agents that inhibit 
sodium-glucose co-transporter 2 (SGLT2), canagliflozin was assessed as monother-
apy treatment for T2DM. METHODS: A systematic literature review identified 36 
trials, which were used to perform a Bayesian NMA to estimate the relative efficacy 
(HbA1c, weight, and systolic blood pressure [SBP]) of canagliflozin monotherapy at 
26±4 weeks compared to dipeptidyl peptidase-4 inhibitors (DPP-4s), sulphonylurea, 
pioglitazone, and SGLT2 inhibitors. Networks of evidence had treatment- and dose-
specific nodes for DPP-4s, pioglitazone, and SGLT2 inhibitors. Relative efficacy was 
evaluated based on absolute differences and Bayesian probabilities (P), where 30%< 
P > 70% were chosen to indicate a smaller and larger effect, respectively. RESULTS: 
Results presented here focus on comparisons to the most relevant anti-hypergly-
caemic therapies in the UK; sitagliptin, gliclazide, pioglitazone, dapagliflozin 10mg, 
and empagliflozin 10mg/25mg. Canagliflozin 300mg was associated with greater 
reductions in HbA1c (Δ –0.29 to –0.52) versus all comparators. Canagliflozin 100mg 
conferred reductions in HbA1c at least as large as other comparator (Δ –0.03 to 
–0.26). Canagliflozin was associated with larger reductions in weight (kg) versus 
all comparators (Δ –0.41 to –7.03), except for canagliflozin 100mg versus empagli-
flozin 25mg, where the reduction was similar (Δ –0.19). Canagliflozin 300mg was 
associated with larger reductions in SBP (Δ –1.06 to –6.29) versus all comparators. 
Canagliflozin 100mg was associated with greater reductions in SBP versus empagli-
flozin 10mg, pioglitazone, and sitagliptin (Δ –1.11 to –4.60) and provided comparable 
reductions in SBP versus dapagliflozin 10mg and empagliflozin 25mg (Δ 0.65 and 
–0.31). CONCLUSIONS: The results of this NMA suggest that canagliflozin 300mg 
monotherapy was associated with consistently greater HbA1c and SBP reductions 
versus all comparators, relevant to UK prescribing habits; while canagliflozin 100mg 
was at least similar. Weight reductions were larger for both doses of canagliflozin 
compared to all comparators.
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OBJECTIVES: To evaluate the clinical effectiveness of Shuddha Guggulu 
(Commiphora mukul) in Hypothyroidism patients. METHODS: A randomized sin-
gle blind clinical study with pretest and posttest design was adopted, where the 
patients were given treatment with specific duration with follow up. In total 379 
patients were selected from the OPD of Muniyal Institute of Ayurvedic Medical 
Sciences Manipal enrolled for the present study out of which 32 were dropped out 
from the study. Thyroid function test, Routine hematological, bio-chemical and 
urine analysis were recorded. The main Signs and Symptoms weight and height 
ratio (BMI – Body Mass Index), Joint pain, Muscle cramps and Tiredness were taken 
for assessment as symptoms grade parameters. Elevation of value of T3 and T4 to 
normal range, decline the TSH value to normal range and Blood Cholesterol also 
taken for the assessment as Laboratory parameters. Data obtained from the above 
mentioned study was statistically analyzed by using the Z test. RESULTS: Shuddha 
Guggulu provided 55.55%. relief in Joint pain and 23.68%, relief in Tiredness which 
were statistically highly significant result p< 0.001, where as in Body mass index, 
Muscle cramps and Anorexia provided 2.2%, 45.45% and 38.71% relief respectively 
which were also statistically highly significant result p< 0.005. Shuddha Guggulu 
provided 23.73% relief in Triiodothyronine (T3), 26.72% relief in Thyroxin (T4), 45.86% 
relief in Thyroid Stimulating Hormone (TSH) and 10.47% relief in Blood Cholesterol 
which were statistically showing highly significant result P < 0.001. CONCLUSIONS: 
Shuddha guggulu appears to be beneficial in those who have metabolic syndrome 
which includes high blood Cholesterol, obesity, and an overall inflammatory pattern. 
Whether it stimulates thyroid function in every condition is still being evaluated.
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OBJECTIVES: To evaluate the efficacy and safety of canagliflozin in combination 
therapy among patients with inadequately controlled type 2 diabetes mellitus 
(T2DM). METHODS: Two review authors independently searched for the relevant 
randomized and controlled clinical trials from the Cochrane Central Register of 
Controlled Trials, MEDLINE, EMBASE, IndMed, LILACS, and clinical trials regis-
try www.clinicaltrials.gov. Primary outcomes for this review included: change in 
HbA1c levels, fasting plasma glucose (FPG) levels and risk of occurrence of urinary 
tract infections; secondary outcomes included mean change in body weight at 26 
weeks and risk of occurrence of genital mycotic infections among both males and 
females separately. We combined results using mean difference (MD) for continu-
ous data, and risk ratio (RR) for dichotomous data. RESULTS: Of the 124 identified 
reports, nine RCTs were included in qualitative analysis and four RCTs with 1568 
participants were eligible for the meta-analysis. All included studies compared 
canagliflozin 300 mg once daily with placebo. We judged that most of the studies 
had low risk of bias or unclear risk of bias in five major domains. Canagliflozin led 
to a significant decrease in HbA1c levels (MD -0.77 [95% CI -0.90, -0.64, p< 0.001]); 
of type 2 diabetes mellitus and cardiovascular events. In order to evaluate the efficacy 
and safety of using metformin to treat prediabetes compared with intensive lifestyle 
intervention, a systematic review was performed. METHODS: Structured searches 
were conducted in the bibliographic databases PubMed/MEDLINE, Cochrane Library, 
LILACS, and CRD until 02/13/2014. Selection criteria included randomized clinical 
trials evaluating the use of metformin compared with intensive lifestyle intervention 
in the treatment of patients with prediabetes. Two reviewers independently scanned 
titles and abstracts for potentially eligible trials. RESULTS: Ramachandran et al. 
showed that intensive lifestyle intervention and metformin reduce the incidence of 
type 2 diabetes mellitus in a native Indian population with impaired glucose tolerance, 
but did not demonstrate additional benefit of the strategy using the combination of 
metformin plus intensive lifestyle intervention in reducing the incidence of type 2 
diabetes mellitus. Knowler et al. have shown that intensive lifestyle intervention and 
metformin were both effective in reducing the incidence of diabetes, but the intensive 
lifestyle intervention was more effective than the use of metformin. CONCLUSIONS: 
Either metformin or a program of intensive lifestyle intervention for the treatment of 
patients with prediabetes are clinically relevant with significant results. The clinical 
effectiveness of each intervention may vary according to the protocol of care and 
dose of medication used. Treatment choices should balance the benefits and adverse 
effects of each method and integrate patient’s personal values, as well as considering 
the feasibility of each intervention according to local characteristics. Further research 
is strongly recommended.
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OBJECTIVES: An extended-release (XR) formulation of metformin has been designed 
to optimize drug delivery with the same antihyperglycemic efficacy as metformin 
immediate-release (IR). A systematic review was conducted to assess efficacy, 
safety and treatment adherence of metformin XR in prediabetes or DM-2 manage-
ment. METHODS: Electronic searches were performed in MEDLINE, LILACS, EMBASE, 
CRD, among others, until May 2014. Search terms included “diabetes mellitus type 
2” and “metformin XR” or “glucophage XR” via MESH controlled vocabulary for the 
Pubmed database and adapted for other databases. Were included: meta-analyses, 
systematic reviews, randomized clinical trials and observational studies with infor-
mation on patients using metformin XR for prediabetes or DM-2 treatment. Two 
reviewers performed the search RESULTS: Nine studies were included and 6,316 
patients were identified. Eight studies evaluated efficacy and all of them safety of 
metformin XR compared with metformin IR or placebo. One study evaluated treat-
ment adherence. Five studies showed a reduction in glycated hemoglobin (HbA1C) 
when compared with placebo, metformin IR or baseline values, and four presented 
no significant differences between metformin XR and metformin IR. Three studies 
found a decrease in fasting plasma glucose and two showed no statistical differ-
ence between metformin IR and XR. Metformin XR showed a beneficial effect on 
lipid profile, however is not possible to affirm superiority compared to metformin 
IR. Metformin XR effect on weight variation seems inconclusive. Regarding safety, 
when compared with placebo, metformin XR may cause dizziness, abdominal pain, 
diarrhea, nausea/vomiting, and urinary tract infection, but is well tolerated by most 
patients without further complications. When compared with metformin IR, all 
studies showed that metformin XR causes less AEs and greater treatment adher-
ence. CONCLUSIONS: In summary, metformin XR showed better or at least similar 
efficacy, and an improved adherence and safety when compared with metformin 
IR. This profile may indicate an important improvement for DM-2 management.
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OBJECTIVES: To assess the efficacy and safety of insulin add-on therapies for Type 
2 diabetes, when insulin with up to two oral anti-diabetes drugs (OADs) does not 
provide adequate glycaemic control. METHODS: A systematic review was conducted 
(MEDLINE, EMBASE and CENTRAL) to identify relevant randomised controlled tri-
als for treatments licensed in the EU at the time of the literature search (July 2013). 
Relative treatment effects were estimated using Bayesian network meta-analysis 
(NMA) via WinBUGs. RESULTS: Seven studies were suitable for inclusion in this 
subgroup analysis at 24 (+/- 6) weeks follow-up and drug classes included were 
SGLT2 inhibitors (dapagliflozin), GLP1 analogues, and DPP4 inhibitors. Trial eligibility 
criteria were broadly similar in terms of qualifying HbA1c, BMI and age. Six stud-
ies had a stable insulin background. The GLP1 study had a ‘treat-to-target’ insulin 
background. Based on the basecase random-effects NMA, all classes of treatment 
resulted in statistically significantly lower HbA1c at follow-up compared to placebo 
(based on the 95% credible interval [CrI]): SGLT2i -0.66 [95%CrI -1.23, -0.09]; GLP1 -0.51 
[95%CrI -0.92, -0.09]; and DPP4 -0.58 [95%CrI -0.87, -0.30]. SGLT2i and GLP1s resulted 
in significantly lower weight at follow-up compared to placebo (-1.86 kg [95%CrI 
-3.64, -0.07] and -1.88kg; [95%CrI -3.27, -0.67] respectively); DPP4i did not result in a 
significant difference in weight compared to placebo (0.06 kg [-0.76, 0.96]). The odds 
of hypoglycaemia for all classes of add-on treatment were not significantly differ-
ent to placebo. CONCLUSIONS: After 24 weeks of treatment SGLT2i when added 
to insulin (+OADs) is non-inferior to DPP4i and GLP1s in terms of HbA1c reduction 
without increasing the risk of hypoglycemia. However, SGLT2i and GLP1s have an 
added benefit of weight loss.
